| CELLDEX THER. DL-,001 |
| USA |
| Gesundheit |
| US15117B2025 / A2PEAB |
| TCE2 (Frankfurt) / CLDX (NASDAQ) |
| FRA:TCE2, ETR:TCE2, TCE2:GR, NASDAQ:CLDX |
| - |
| https://www.celldex.com/ |
|
Celldex Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted immunotherapies for cancer and other serious diseases. Its research platforms leverage novel antibody the..
>Volltext.. |
| 1696.73 Mio. EUR |
| 1264.81 Mio. EUR |
| 1.34 Mio. EUR |
| -245.54 Mio. EUR |
| -223.73 Mio. EUR |
| -3.37 EUR |
| 2.02 Mio. EUR |
| 24.96 Mio. EUR |
| -182.39 Mio. EUR |
| 10.08 |
| -80.59% |
| -44.47% |
| - |
| - |
| - |
| - |
| CELLDEX |
| 02.04.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|